Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $108.15 Average PT from Brokerages

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $113.6923.

Several analysts have recently weighed in on PTGX shares. Jefferies Financial Group restated a “buy” rating and set a $121.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. HC Wainwright upped their target price on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. TD Cowen increased their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Leerink Partners raised their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Finally, Citizens Jmp lifted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday.

Protagonist Therapeutics Stock Up 0.5%

Protagonist Therapeutics stock opened at $99.36 on Tuesday. Protagonist Therapeutics has a 52 week low of $42.85 and a 52 week high of $107.84. The business has a 50-day simple moving average of $99.40 and a 200 day simple moving average of $89.42. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of -54.90 and a beta of 1.89.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. On average, research analysts anticipate that Protagonist Therapeutics will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Arturo Md Molina sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $104.79, for a total value of $1,571,850.00. Following the completion of the sale, the insider owned 84,115 shares in the company, valued at $8,814,410.85. The trade was a 15.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lewis T. Williams sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 138,215 shares of company stock worth $13,866,186 over the last ninety days. Corporate insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in Protagonist Therapeutics in the fourth quarter worth $27,000. Salomon & Ludwin LLC bought a new stake in Protagonist Therapeutics in the third quarter worth $29,000. EverSource Wealth Advisors LLC lifted its stake in Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC bought a new stake in Protagonist Therapeutics in the third quarter worth $62,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.